penpulimabTQB2618NCT05400876cHLr/r cHLr/r lymphoma
…ed in the dose-escalation phase, and TQB2618 (600 mg, Q3W) plus penpulimab (200 mg, Q3W) was selected as the RP2D. In the dose-expansion p…
1articles mentioning drugs
5drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: TQB2618 ×
TQB2618
This drug is selected. Its supporting articles are shown below.